Raman Spectroscopy In-Depth Focus
In this Raman Spectroscopy In-Depth Focus: Subvisible particle identification in protein-based formulations by Raman spectroscopy; Raman spectroscopy as a blood glucose monitoring tool...
List view / Grid view
Articles
The regulatory acceptance of rapid microbiological methods
In the last issue of European Pharmaceutical Review (vol 22, issue 2), Jeanne Moldenhauer suggested the pharmaceutical industry has moved at a “snail’s pace” in terms of implementing rapid microbiological methods (RMM).
Microorganisms and a new horizon of scientific discoveries
The simplest form of life is composed of single-celled microorganisms which are thought to have appeared around 3.5x109 years ago.1 Interestingly, evidence has shown that chloroplasts and mitochondria were once free-living microorganisms that became incorporated into eukaryotic cells and eventually became energy-producing organelles.1 Biodiversity enables microorganisms to survive in extreme…
Regulation of orphan drugs within the EU
Simply put, an orphan drug is indicated for the treatment of a very rare disease. Such diseases are often due to genetic defects and therefore children and newborns are affected to a great extent1.
Microfluidic techniques for cancer therapies
Perhaps the most significant challenge in all of medicine is the need for more effective treatments for cancer, which causes one of every four deaths in the United States and bears a direct cost to our healthcare system of close to $100bn annually.
Guide To Testing Services
Welcome to European Pharmaceutical Review’s Guide to Testing Services, the second in our new series of ‘Guide to …’ supplements. In this edition, five leading testing service suppliers explain how their service offering meets current industry needs...
Subvisible particle identification in protein-based formulations by Raman spectroscopy
Subvisible particles in protein-based formulations can have different origins. Particles can be extrinsic (unexpected foreign material), intrinsic (from the production environment or primary packaging), and inherent (from the formulation). It is important that inherent particles (protein agglomerates) are distinguished from the other two types and that the extrinsic and intrinsic…
Separation and purification applications for mutagenic impurities
Classically, isolation of key intermediates and the resultant active pharmaceutical ingredient (API) has formed the basis of clean up and purification strategies within the pharmaceutical industry...
Personalised medicine, batch size of ONE, the new challenge to fill-finish?
Wenzel Novak PhD gives some considerations on container, environment, process and automation for small batch sizes in the downstream process of fill-finish…
Formulation Development & Delivery In-Depth Focus
In this Formulation Development & Delivery In-Depth Focus: A report on the use of freeze-drying to develop orally disintegrating tablets; a review of mucosal drug delivery; an interview on drug delivery through the skin; and a profile of three analytical technologies used to develop drug delivery systems...
Scientific Poster Gallery 2017
In this supplement, we've brought together a collection of interesting posters from leading companies in order to celebrate cutting-edge research in the pharmaceutical industry and to share with our readers some of the varied work being carried out by their colleagues...
Issue #3 2017 – Digital version
In Issue #3 2017: In-Depth Focuses covering Raman Spectroscopy, Separations & Purifications, Formulation Development & Delivery; Guide To Testing Services; GMP and mutual recognition; Regulatory Insight; RMMs; Microbiology Series; and much more...
83% of life science leaders believe blockchain will be adopted within 5 years
Just under a quarter (22%) of life science companies already using or experimenting with blockchain, but industry collaboration over security and storage standards is needed…
Shire on Haemophilia: How to treat a bleeding disorder
We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research...
Risk, benefit or cost: What stops patients from receiving a diagnostic test?
Diagnostic tests can help identify disease and disease probability in patients, leading to earlier treatment, but what’s the real cost?
